These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 32142862)

  • 21. Quantitative assessment of gait and neurochemical correlation in a classical murine model of Parkinson's disease.
    Wang XH; Lu G; Hu X; Tsang KS; Kwong WH; Wu FX; Meng HW; Jiang S; Liu SW; Ng HK; Poon WS
    BMC Neurosci; 2012 Nov; 13():142. PubMed ID: 23151254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Neuroprotective Effects of GPR4 Inhibition through the Attenuation of Caspase Mediated Apoptotic Cell Death in an MPTP Induced Mouse Model of Parkinson's Disease.
    Haque ME; Azam S; Akther M; Cho DY; Kim IS; Choi DK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
    J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.
    Santos DB; Colle D; Moreira EL; Hort MA; Godoi M; Le Douaron G; Braga AL; Assreuy J; Michel PP; Prediger RD; Raisman-Vozari R; Farina M
    Mol Neurobiol; 2017 Mar; 54(2):1513-1530. PubMed ID: 26852411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice.
    Yabuki Y; Ohizumi Y; Yokosuka A; Mimaki Y; Fukunaga K
    Neuroscience; 2014 Feb; 259():126-41. PubMed ID: 24316474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MPTP-induced parkinsonism in mice alters striatal and nigral xCT expression but is unaffected by the genetic loss of xCT.
    Bentea E; Sconce MD; Churchill MJ; Van Liefferinge J; Sato H; Meshul CK; Massie A
    Neurosci Lett; 2015 Apr; 593():1-6. PubMed ID: 25766755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
    Breidert T; Callebert J; Heneka MT; Landreth G; Launay JM; Hirsch EC
    J Neurochem; 2002 Aug; 82(3):615-24. PubMed ID: 12153485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
    Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW
    Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential expression of RET and GDNF family receptor, GFR-α1, between striatum and substantia nigra following nigrostriatal lesion: A case for diminished GDNF-signaling.
    Kasanga EA; Han Y; Navarrete W; McManus R; Shifflet MK; Parry C; Barahona A; Manfredsson FP; Nejtek VA; Richardson JR; Salvatore MF
    Exp Neurol; 2023 Aug; 366():114435. PubMed ID: 37178997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delivery of CDNF by AAV-mediated gene transfer protects dopamine neurons and regulates ER stress and inflammation in an acute MPTP mouse model of Parkinson's disease.
    Nam J; Richie CT; Harvey BK; Voutilainen MH
    Sci Rep; 2024 Jul; 14(1):16487. PubMed ID: 39019902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of m6A modification regulators in the substantia nigra and striatum of MPTP-induced Parkinson's disease mice.
    Yu Z; Huang L; Xia Y; Cheng S; Yang C; Chen C; Zou Z; Wang X; Tian X; Jiang X; Zhou L
    Neurosci Lett; 2022 Nov; 791():136907. PubMed ID: 36209975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model.
    Rai SN; Yadav SK; Singh D; Singh SP
    J Chem Neuroanat; 2016 Jan; 71():41-9. PubMed ID: 26686287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
    Price DA; Martinez AA; Seillier A; Koek W; Acosta Y; Fernandez E; Strong R; Lutz B; Marsicano G; Roberts JL; Giuffrida A
    Eur J Neurosci; 2009 Jun; 29(11):2177-86. PubMed ID: 19490092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebral alterations in a MPTP-mouse model of Parkinson's disease--an immunocytochemical study.
    Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
    J Neural Transm (Vienna); 2003 Oct; 110(10):1129-44. PubMed ID: 14523625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
    Muthian G; Mackey V; King J; Charlton CG
    Neuroscience; 2010 Sep; 169(3):1085-93. PubMed ID: 20540993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.
    Oiwa Y; Eberling JL; Nagy D; Pivirotto P; Emborg ME; Bankiewicz KS
    Front Biosci; 2003 Sep; 8():a155-66. PubMed ID: 12957824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tyrosine hydroxylase expression and activity in nigrostriatal dopaminergic neurons of MPTP-treated mice at the presymptomatic and symptomatic stages of parkinsonism.
    Kozina EA; Khakimova GR; Khaindrava VG; Kucheryanu VG; Vorobyeva NE; Krasnov AN; Georgieva SG; Kerkerian-Le Goff L; Ugrumov MV
    J Neurol Sci; 2014 May; 340(1-2):198-207. PubMed ID: 24768159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Executive function deficits and glutamatergic protein alterations in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
    Pflibsen L; Stang KA; Sconce MD; Wilson VB; Hood RL; Meshul CK; Mitchell SH
    J Neurosci Res; 2015 Dec; 93(12):1849-64. PubMed ID: 26332770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initial Molecular Mechanisms of the Pathogenesis of Parkinson's Disease in a Mouse Neurotoxic Model of the Earliest Preclinical Stage of This Disease.
    Kolacheva A; Pavlova E; Bannikova A; Bogdanov V; Ugrumov M
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.